Lower priority at this years official agenda were.

The theme of the 22nd Meeting of the PCB was TB / HIV and questions about the diagnosis and treatment of tuberculosis in people with HIV and the need for closer collaboration between HIV and TB programs were addressed. – Lower priority at this year’s official agenda were; gender sensitivity of AIDS responses, a second independent evaluation of UNAIDS, The Committee wille Global Task Team Independent Assessment and the process of nomination for a new Executive Director of UNAIDS.

At the hearing, the United States took over as the new chairman of Thailand, the Board appointed Ethiopia Deputy Chairman Deputy Chairman and Guatemala rapporteur. This year’s meeting in Chiang Mai more than 300 more than 300 participants and observers from Member States, international organizations, civil society and NGOs.On January 12, 2010, Biogen Idec announced the submission of Marketing Authorization Application to the European Medicinal Products Agency. Prolonged release fampridine tablets act for the improve walking in adult people living with MS the Company has also a a New Drug Submission sent to Health Canada.

AMPYRA may be an important therapy in reducing of impact of such debilitating condition. – We congratulate our partner, Acorda Therapeutics, on this important achievement and forward to working together with regulators outside of United States of America this therapy for any persons with MS making. .. Ampyra in the U.S. From Acorda Therapeutics,: are marketed . AMPYRA is an extended release tablet formula the drug dalfampridine . Biogen Idec is fampridine fampridine prolonged release tablet a prolonged release tablet to markets outside the U.S. Use people with MS, impaired walking ability is one of most prevalent and difficult aspects of to the disease, said Alfred Sandrock, Senior Vice President, Neurology Research and development, Biogen Idec.